Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)vsZoetis Inc (ZTS)
AMRX
Amneal Pharmaceuticals, Inc. Class A Common Stock
$17.01
+0.83%
HEALTHCARE · Cap: $6.01B
ZTS
Zoetis Inc
$72.97
+0.15%
HEALTHCARE · Cap: $30.40B
Smart Verdict
WallStSmart Research — data-driven comparison
Zoetis Inc generates 206% more annual revenue ($9.53B vs $3.12B). ZTS leads profitability with a 27.7% profit margin vs 5.0%. ZTS trades at a lower P/E of 12.0x. ZTS earns a higher WallStSmart Score of 58/100 (C).
AMRX
Buy56
out of 100
Grade: C
ZTS
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+28.5%
Fair Value
$20.56
Current Price
$17.01
$3.55 discount
Margin of Safety
+11.3%
Fair Value
$145.00
Current Price
$72.97
$72.03 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 157.1% YoY
Attractively priced relative to earnings
Every $100 of equity generates 83 in profit
Strong operational efficiency at 40.7%
Safe zone — low bankruptcy risk
Keeps 28 of every $100 in revenue as profit
Areas to Watch
Premium valuation, high expectations priced in
5.0% margin — thin
Trading at 170.1x book value
ROE of -881.0% — below average capital efficiency
Trading at 9.3x book value
1.2% earnings growth
Expensive relative to growth rate
Revenue declined 0.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : AMRX
The strongest argument for AMRX centers on EPS Growth.
Bull Case : ZTS
The strongest argument for ZTS centers on P/E Ratio, Return on Equity, Operating Margin. Profitability is solid with margins at 27.7% and operating margin at 40.7%.
Bear Case : AMRX
The primary concerns for AMRX are P/E Ratio, Profit Margin, Price/Book. Debt-to-equity of 84.54 is elevated, increasing financial risk.
Bear Case : ZTS
The primary concerns for ZTS are Price/Book, EPS Growth, PEG Ratio. Debt-to-equity of 2.93 is elevated, increasing financial risk.
Key Dynamics to Monitor
AMRX profiles as a value stock while ZTS is a declining play — different risk/reward profiles.
AMRX carries more volatility with a beta of 1.24 — expect wider price swings.
AMRX is growing revenue faster at 9.9% — sustainability is the question.
ZTS generates stronger free cash flow (538M), providing more financial flexibility.
Bottom Line
ZTS scores higher overall (58/100 vs 56/100), backed by strong 27.7% margins. AMRX offers better value entry with a 28.5% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amneal Pharmaceuticals, Inc. Class A Common Stock
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Amneal Pharmaceuticals, Inc. develops, licenses, manufactures, markets and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company is headquartered in Bridgewater, New Jersey.
Zoetis Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?